Recent Updates
Recently added Catalysts
ATYR Positive Sentiment Score: 75/100

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Key Takeaway: aTyr Pharma announced that its CEO, Sanjay S. Shukla, will present at the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 13-16, 2025, in San Francisco. The presentation will highlight the company’s first-in-class medicines developed from its proprietary tRNA synthetase platform. Subsequently, a one-on-one meeting with registered investors is planned, enhancing engagement opportunities. A webcast of the presentation will also be available for investors on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • aTyr Pharma will present at a prestigious healthcare conference.
  • The CEO's participation could enhance investor interest and visibility.
  • The company focuses on innovative therapies from its unique tRNA synthetase platform.

Full Press Release Details

SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place January 13 – 16, 2025, in San Francisco, CA.
Details of the presentation appear below:
Conference: 43rd Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 16, 2025
Location: San Francisco, CA
Format: Corporate Presentation
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contact investorrelations@atyrpharma.com.
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Director, Investor Relations and Public Affairs

Tags

Frequently Asked Questions

What is aTyr Pharma's main focus?

aTyr Pharma focuses on discovering first-in-class medicines using its tRNA synthetase platform.

When is the J.P. Morgan Healthcare Conference?

The 43rd Annual J.P. Morgan Healthcare Conference is from January 13 to 16, 2025.

How can I access the conference presentation?

The presentation will be available as a webcast on aTyr’s Investor website.

What is efzofitimod?

Efzofitimod is a first-in-class biologic for treating interstitial lung disease.

Who will be presenting at the conference?

Sanjay S. Shukla, M.D., the CEO, will present at the conference.

Last updated: Dec 17, 2024